[go: up one dir, main page]

HK8395A - Human factor VIII, compositions containing it, methods and materials for use in its production - Google Patents

Human factor VIII, compositions containing it, methods and materials for use in its production Download PDF

Info

Publication number
HK8395A
HK8395A HK8395A HK8395A HK8395A HK 8395 A HK8395 A HK 8395A HK 8395 A HK8395 A HK 8395A HK 8395 A HK8395 A HK 8395A HK 8395 A HK8395 A HK 8395A
Authority
HK
Hong Kong
Prior art keywords
factor viii
dna
human factor
protein
fragment
Prior art date
Application number
HK8395A
Other languages
English (en)
French (fr)
Inventor
Jeffrey Capon Daniel
Allen Vehar Gordon
Mark Lawn Richard
Irwin Wood William
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24410850&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK8395(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of HK8395A publication Critical patent/HK8395A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1051—Gene trapping, e.g. exon-, intron-, IRES-, signal sequence-trap cloning, trap vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6832—Enhancement of hybridisation reaction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Claims (15)

1. DNA Isolat, das ein Human Faktor VIII Polpeptid der in Fig. 10 der vorliegenden Beschreibung dargestellten Aminosäuresequenz kodiert, oder ein Derivat desselben, das die Fähigkeit besitzt, Mängel an Human Faktor VIII zu korrigieren.
2. Rekombinanter Expressionsvektor, der betriebsbereit eine DNA enthält, die ein Human Faktor VIII Polypeptid der hierin in Fig. 10 dargestellten Aminosäuresequenz kodiert, oder ein Derivat derselben, das die Fähigkeit besitzt, Mängel an Human Faktor VIII zu korrigieren.
3. Vektor pAML3P.8c1, der dazu verwendet wird, die BHK Zellenlinie mit der ATCC-Nr. CRL8544 zu transfizieren.
4. Kultur von Zellen, die fähig sind, rekombinanten funtkionellen Human Faktor VIII zu produzieren, welche Zellen mit dem Expressionsvektor nach Anspruch 3 transfiziert wurden.
5. Zellenkultur nach Anspruch 4, die durch Transfektion von BHK Zellen erhalten wurde.
6. BHK Zellenlinie mit der ATCC-NR. CRL8544 und Mutanten oder Varianten derselben, die fähig sind, ein Human Faktor VIII Polypeptid zu exprimieren.
7. Rekombinanter Organismus, der mit DNA, die ein Human Faktor VIII Polpeptid der hierin in Fig. 10 dargestellten Aminosäuresequenz kodiert, oder einem Derivat desselben, mit der Fähigkeit transfiziert ist, Mängel an Human Faktor VIII zu korrigieren, um fähig zu sein, diese DNA zu exprimieren.
8. Verfahren umfassend die Produktion eines Polypeptides der hierin in Fig. 10 dargestellten Aminosäuresequenz oder eines Derivates desselben, das fähig ist, Mängel an Human Faktor VIII zu korrigieren, welches Verfahren die Expression der das genannte Polypeptid kodierenden DNA in einem rekombinanten Wirtsorganismus umfaßt, der mit der genannten DNA transfiziert ist.
9. Verfahren nach Anspruch 8, worin der Wirtsorganismus eine eukaryotische Zelle ist.
10. Verfahren nach Anspruch 9, worin die eukaryotische Zelle aus einer Zellenlinie aus den Eierstöcken von Chinesischen Hamstern (CHO) herrührt.
11. Verfahren nach Anspruch 9, worin die eukaryotische Zelle aus einer Zellenlinie aus den Nieren von Babyhamstern (BHK) herrührt.
12. Verfahren nach einem der Ansprüche 8 bis 11, welches zusätzlich den Schritt der Gewinnung des Polypeptidproduktes umfaßt.
13. Verfahren, das folgend auf die Herstellung des Polypeptids nach einem Verfahren der Ansprüche 8 bis 12 die Verwendung des Polypeptidproduktes für die Herstellung von Arzneimitteln umfaßt.
14. Pharmazeutisches Zusammensetzung, die ein Faktor VIII Polypeptid, das allein aus einer einzigen in Fig. 10 hierin dargestellten Aminosäuresequenz herrührt, oder ein Derivat desselben, das fähig ist, Mängel an Human Faktor VIII zu korrigieren, zusammen mit einem pharmazeutisch verträglichen Trägermittel enthält.
15. Pharmazeutische Zusammensetzung nach Anspruch 14, die im wesentlichen frei von Protein oder anderen Materialien ist, die üblicherweise mit Human Faktor VIII assoziiert sind, wenn er aus seiner nativen, Plasma enthaltenden Umgebung isoliert wird.
HK8395A 1984-04-20 1995-01-19 Human factor VIII, compositions containing it, methods and materials for use in its production HK8395A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60231284A 1984-04-20 1984-04-20

Publications (1)

Publication Number Publication Date
HK8395A true HK8395A (en) 1995-01-27

Family

ID=24410850

Family Applications (1)

Application Number Title Priority Date Filing Date
HK8395A HK8395A (en) 1984-04-20 1995-01-19 Human factor VIII, compositions containing it, methods and materials for use in its production

Country Status (23)

Country Link
EP (2) EP0385558A3 (de)
JP (2) JP2799338B2 (de)
KR (1) KR850007275A (de)
AR (1) AR241314A1 (de)
AT (1) ATE60087T1 (de)
AU (2) AU601358B2 (de)
CA (2) CA1341395C (de)
DE (1) DE3581312D1 (de)
DK (1) DK164876C (de)
ES (1) ES8607397A1 (de)
FI (1) FI86885C (de)
GR (1) GR850947B (de)
HK (1) HK8395A (de)
HU (1) HU202275B (de)
IE (1) IE57677B1 (de)
IL (1) IL74909A (de)
LU (1) LU88546I2 (de)
MY (1) MY102029A (de)
NL (1) NL940016I2 (de)
NO (1) NO174934C (de)
NZ (1) NZ211824A (de)
PT (1) PT80292B (de)
ZA (1) ZA852864B (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657894A (en) * 1983-03-31 1987-04-14 Scripps Clinic & Research Foundation New factor VIII coagulant polypeptides
WO1985001961A1 (en) * 1983-10-28 1985-05-09 Genetics Institute Production of factor viii and related products
US5045455A (en) * 1984-01-12 1991-09-03 Chiron Corporation Factor VIII:C cDNA cloning and expression
US5004804A (en) * 1984-01-12 1991-04-02 Nordisk Gentofte Method and composition for preparation of factor VIIIC
DE3586402T3 (de) * 1984-01-12 2004-12-23 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Proteinzusammensetzung mit Koagulations-wirkung und Verfahren zu ihrer Herstellung.
US4716117A (en) * 1984-10-26 1987-12-29 Chiron Corporation Monoclonal antibodies to factor VIIIC
US7138505B1 (en) 1984-01-12 2006-11-21 Novartis Vaccines And Diagnostics, Inc. Factor VIII:C nucleic acid molecules
ZA852099B (en) * 1984-03-26 1985-12-24 Meloy Lab Recombinant factor viii-c.
IL74909A (en) 1984-04-20 1992-01-15 Genentech Inc Preparation of functional human factor viii and dna sequences,expression vectors,transformed microorganisms and cell lines used therein
EP0182448A3 (de) * 1984-08-24 1987-10-28 Genetics Institute, Inc. Verfahren zur Herstellung von Faktor VIII und verwandte Produkte
US4868112A (en) * 1985-04-12 1989-09-19 Genetics Institute, Inc. Novel procoagulant proteins
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
FR2599754B1 (fr) * 1986-06-06 1989-12-29 Transgene Sa Procede de preparation de facteur viii a partir de cellules de mammiferes
EP0251843A1 (de) * 1986-06-06 1988-01-07 Transgene S.A. Verfahren zur Herstellung von Faktor VIII aus Säugerzellen
DE3769872D1 (de) 1986-07-11 1991-06-13 Miles Inc Herstellung von rekombinantem protein.
IL83192A (en) * 1986-07-18 1992-11-15 Gist Brocades Nv Method for the preparation of proteins with factor viii activity by microbial host cells;expression vectors,host cells,antibodies
AU613316B2 (en) * 1986-09-12 1991-08-01 Genentech Inc. Improved recombinant expression
WO1988005825A1 (en) * 1987-01-30 1988-08-11 Biogen N.V. A method for producing factor viii in high yield
US6060447A (en) * 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
IE69026B1 (en) 1987-06-12 1996-08-07 Immuno Ag Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
EP0294910B1 (de) * 1987-06-12 1996-09-11 Immuno Ag Proteine mit Faktor-VIII-Aktivität, Verfahren zu deren Herstellung unter Verwendung von genetisch modifizierten Zellen und diese enthaltende pharmazeutische Zusammensetzungen
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
JPH0387173A (ja) * 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
JP2791418B2 (ja) 1987-12-02 1998-08-27 株式会社ミドリ十字 異種蛋白質の製造方法、組換えｄｎａ、形質転換体
FR2642767B1 (fr) * 1989-01-19 1993-10-01 Transgene Sa Vecteurs d'expression de proteines heterologues dans les cellules eucaryotes, lignees cellulaires obtenues et procede pour leur preparation
NZ237244A (en) * 1990-03-02 1992-10-28 Bio Technology General Corp Cloning and production of human von willebrand factor analogues and compositions thereof
US5849536A (en) * 1990-03-02 1998-12-15 Bio-Technology General Corp. Cloning and production of human von willebrand factor GPIb binding domain polypeptides and methods of using same
US6008193A (en) * 1990-03-02 1999-12-28 Bio-Technology General Corp. Methods of using human von Willebrand factor GPIb binding domain polypeptides
US5279956A (en) * 1991-06-24 1994-01-18 The Scripps Research Institute Activated protein C polypeptides and anti-peptide antibodies, diagnostic methods and systems for inhibiting activated protein C
DK53792D0 (da) * 1992-04-24 1992-04-24 Novo Nordisk As Fremgangsmaade til fremstilling af proteiner
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
SE9303601D0 (sv) * 1993-11-01 1993-11-01 Kabi Pharmacia Ab Improved cell cultivation method and medium
US6288030B1 (en) 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
IL113010A0 (en) * 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
US5561053A (en) * 1994-08-05 1996-10-01 Genentech, Inc. Method for selecting high-expressing host cells
SE9403915D0 (sv) * 1994-11-14 1994-11-14 Annelie Almstedt Process A
SE503424C2 (sv) * 1994-11-14 1996-06-10 Pharmacia Ab Process för rening av rekombinant koagulationsfaktor VIII
GB9501040D0 (en) 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
US7005505B1 (en) 1995-08-25 2006-02-28 Genentech, Inc. Variants of vascular endothelial cell growth factor
US6020473A (en) * 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US5910481A (en) * 1995-11-13 1999-06-08 Immuno Ag Hybrid proteins with modified activity
AT405740B (de) * 1996-12-13 1999-11-25 Immuno Ag Von willebrand-faktor-derivat sowie ein verfahren zur isolierung von proteinen
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US6221349B1 (en) 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
SE9901379D0 (sv) 1999-04-19 1999-04-19 Pharmacia & Upjohn Ab Receptor structures
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
JP4663837B2 (ja) * 1999-12-24 2011-04-06 一般財団法人化学及血清療法研究所 第▲ｖｉｉｉ▼因子を主成分とする血小板減少に伴う出血疾患の予防・治療用医薬組成物
CZ303929B6 (cs) * 2000-03-22 2013-07-03 Octapharma Biopharmaceuticals Gmbh Mutein faktoru VIII, odpovídající DNA sekvence, vektor a hostitelská bunka, farmaceutická kompozice, zpusob produkce muteinu a imortalizovaná lidská bunecná linie
WO2003013244A1 (en) 2001-08-03 2003-02-20 The Government Of The United State Of America, As Represented By The Secretary Of The Department Of Health And Human Services Oral treatment of hemophilia
AU2002358047A1 (en) * 2001-11-28 2003-06-10 Sandoz Ag Method for producing a recombinant polypeptide
EP1520008B1 (de) 2002-07-09 2012-09-05 Baxter International Inc. Tierproteinfreies zellkulturmedium
DK2292779T3 (en) 2003-09-30 2017-02-27 Univ Pennsylvania ADENOASS-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME AND APPLICATIONS THEREOF
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
EP1707634A1 (de) 2005-03-29 2006-10-04 Octapharma AG Verfahren zur Isolierung von rekombinant hergestellten Proteinen
WO2006110689A2 (en) 2005-04-07 2006-10-19 The Trustees Of The University Of Pennsylvania Method of increasing the function of an aav vector
EP1739179A1 (de) 2005-06-30 2007-01-03 Octapharma AG Serumfreie stabile Transfektion und Produktion von rekombinanten humanen Proteinen in humanen Zelllinien
PT1974014T (pt) 2006-01-04 2017-05-26 Baxalta Inc Meios de cultura celulares livres de oligopeptídeos
WO2011095604A1 (en) 2010-02-04 2011-08-11 Octapharma Biopharmaceuticals Gmbh Half-life prolongation of proteins
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
EP2553106A2 (de) 2010-03-29 2013-02-06 The Trustees Of The University Of Pennsylvania System für pharmakologisch induzierte transgene ablation
EP2675902B1 (de) 2011-02-17 2019-03-27 The Trustees Of The University Of Pennsylvania Zusammensetzungen und method zur veränderung der gewebespezifität und verbesserung des aav9-vermittleten gentransfers
WO2015012924A2 (en) 2013-04-29 2015-01-29 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and use thereof
ES3009565T3 (en) 2015-04-16 2025-03-27 Univ Emory Recombinant promoters and vectors for protein expression in liver and use thereof
CN111504887B (zh) * 2020-05-09 2023-05-09 苏州四正柏生物科技有限公司 一种溶血素及其制备方法
AU2021320419A1 (en) 2020-08-07 2023-03-09 Amicus Therapeutics, Inc. Vesicle targeting proteins and uses of same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361509A (en) * 1981-12-14 1982-11-30 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
JP2625412B2 (ja) * 1982-08-04 1997-07-02 ブリティッシュ・テクノロジー・グループ・リミテッド ヒト第９因子ポリペプチドをコードするｃｄｎａ
CA1341506C (en) * 1983-03-31 2006-06-06 Theodore S. Zimmerman Factor viii coagulant polypeptides and monoclonal antibodies to them
WO1985001961A1 (en) * 1983-10-28 1985-05-09 Genetics Institute Production of factor viii and related products
DE3586402T3 (de) * 1984-01-12 2004-12-23 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Proteinzusammensetzung mit Koagulations-wirkung und Verfahren zu ihrer Herstellung.
ZA852099B (en) * 1984-03-26 1985-12-24 Meloy Lab Recombinant factor viii-c.
IL74909A (en) 1984-04-20 1992-01-15 Genentech Inc Preparation of functional human factor viii and dna sequences,expression vectors,transformed microorganisms and cell lines used therein
JPS60224492A (ja) * 1984-04-24 1985-11-08 Yuu Honshiyo 異種遺伝子の結合法

Also Published As

Publication number Publication date
ZA852864B (en) 1986-12-30
AR241314A1 (es) 1992-05-29
MY102029A (en) 1992-02-29
EP0160457B1 (de) 1991-01-16
DK164876C (da) 1993-01-18
GR850947B (de) 1985-07-17
CA1341395C (en) 2002-10-22
HUT37654A (en) 1986-01-23
JP2777043B2 (ja) 1998-07-16
DE3581312D1 (de) 1991-02-21
ES8607397A1 (es) 1986-06-01
FI851497A0 (fi) 1985-04-15
IL74909A0 (en) 1985-07-31
ES542296A0 (es) 1986-06-01
AU601358B2 (en) 1990-09-13
AU4134585A (en) 1985-10-24
DK176885D0 (da) 1985-04-19
EP0160457A1 (de) 1985-11-06
DK164876B (da) 1992-08-31
NO174934B (no) 1994-04-25
HU202275B (en) 1991-02-28
FI86885B (fi) 1992-07-15
KR850007275A (ko) 1985-12-02
IE850998L (en) 1985-10-20
IL74909A (en) 1992-01-15
AU5295890A (en) 1990-08-30
NZ211824A (en) 1991-05-28
LU88546I2 (fr) 1995-03-01
NL940016I1 (nl) 1994-10-17
CA1341468C (en) 2004-12-14
NO851563L (no) 1985-10-21
NL940016I2 (nl) 2000-08-01
NO174934C (no) 1994-08-03
FI851497L (fi) 1985-10-21
DK176885A (da) 1985-10-21
PT80292A (en) 1985-05-01
FI86885C (fi) 1992-10-26
JP2799338B2 (ja) 1998-09-17
EP0385558A2 (de) 1990-09-05
IE57677B1 (en) 1993-02-24
JPH0640942A (ja) 1994-02-15
JPS60243023A (ja) 1985-12-03
PT80292B (pt) 1987-10-20
EP0385558A3 (de) 1990-12-27
ATE60087T1 (de) 1991-02-15

Similar Documents

Publication Publication Date Title
EP0160457B1 (de) Menschlicher Faktor VIII, diesen enthaltende Zusammensetzungen sowie Verfahren und Materialien, die für seine Herstellung Verwendung finden
US5654147A (en) Method of hybridization using oligonucleotide probes
EP0162067B1 (de) Herstellung des faktors viii und damit verwandte erzeugnisse
JP2584443B2 (ja) 活性化▲ｉ▼▲ｘ▼因子の高収率産生
KR970002915B1 (ko) 제ⅷ인자 활성을 가지는 신규한 단백질 : 유전공학-제조 세포를 사용하는 그의 제조방법 및 그것을 함유하는 의약 조성물
AU591671B2 (en) Von willebrand factor
AU610059B2 (en) Method of producing a recombinant protein complex having human factor VIII:C activity
JPS63301797A (ja) 組織因子タンパク質を製造するためのデオキシリボ核酸
EP0294910B1 (de) Proteine mit Faktor-VIII-Aktivität, Verfahren zu deren Herstellung unter Verwendung von genetisch modifizierten Zellen und diese enthaltende pharmazeutische Zusammensetzungen
EP0182448A2 (de) Verfahren zur Herstellung von Faktor VIII und verwandte Produkte
WO1993000357A1 (en) Therapeutic polypeptides based on von willebrand factor
EP0648268A1 (de) Therapeutische fragmente des von willebrand faktors
AU1809788A (en) Novel proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20050417